Skip to main content
Premium Trial:

Request an Annual Quote

Ben Bowen, William Albright, Ben Bulkley, Bernd Brust, John Radak, Kelli Richard

Ben Bowen has been appointed vice president of business development at Biolog.
Bowen will be responsible for launching Biolog’s forthcoming mammalian cell Phenotype Microarray product. Previously, Bowen served as vice president of discovery research at Lynx Therapeutics. He has also worked at Pioneer Hi-Bred (now part of DuPont).

ForteBio this week named William Albright as the company’s chief financial officer.
Albright most recently served as chief financial officer and senior vice president of finance and operations at Xenogen, now part of Caliper Life Sciences. He has also held executive positions at FlowMedica, Nexell Therapeutics, LocalMed, Connectics, and ChemTrak. He holds an MBA from Harvard Business School, and a BS and MS in biology from StanfordUniversity.

Ben Bulkley and Invitrogen have mutually agreed for his departure from the company, Invitrogen said in a document filed with the US Securities and Exchange Commission this week. Bulkley is senior vice president of commercial operations. His departure date is Jan. 31. Bernd Brust, senior vice president of global sales, will replace him.

The company also announced the resignation of John Radak as VP for finance and principal accounting officer, effective Jan. 31. He will be replaced by Kelli Richard, who has been corporate controller at Invitrogen since August 2005.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.